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Purpose: Thymoglobulin (ATG) given before allogeneic hema-
topoietic stem cell transplantation (HSCT) with unrelated donors
reduces acute graft-versus-host disease (GVHD). However, the
possible role of serum concentration of rabbit ATG for the sub-
sequent development of acute GVHD after HSCT is unknown.
Methods: The serum concentration of rabbit IgG was analyzed by
enzyme-linked immunosorbent assasy in 61 patients after unre-
lated donor HSCT. Doses of ATG as part of the conditioning
ranged between 4 and 10 mg/kg. Stem cell source was bone
marrow (BM) in 28 cases and peripheral blood (PBSC) in 33.
Conditioning was mainly cyclophosphamide combined with total
body irradiation (TBI) or busulfan. Most patients received GVHD
prophylaxis with cyclosporine and methotrexate. Results: Even
though we found a good correlation between given ATG dose and
serum concentration of rabbit IgG after transplant (r 0.67), there
was a wide variation of rabbit IgG levels within each dose group.
After administration, levels of rabbit IgG decreased slowly and
could still be detected up to 5 weeks after HSCT. We found a
correlation between grade of acute GVHD and concentration of
rabbit IgG in serum obtained before transplantation (P  .017).
Patients with serum levels of rabbit IgG 70 mg/ml before HSCT
had very low risk for developing acute GVHD grades II-IV com-
pared with those with  70 mg/ml (11% vs 53%; P  .001).
Conclusion: Measuring rabbit IgG levels in patients receiving
ATG as prophylaxis against GVHD after HSCT may be a helpful
tool in decreasing the risk of severe GVHD.
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GENERATION OF TOLEROGENIC DENDRITIC CELLS AND REGULATORY
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TOPHERESIS-INDUCED APOPTOTIC CELLS
Campbell, K.1; Huber, J.1; Rosenberg, A.1; Peters, C.1; Harriman, G.1;
Strobl, F.1; Peritt, D.1; Schwarz, A.2; Maeda, A.2; Schwarz, T.2 1.
Therakos, Inc., Exton, PA; 2. University Clinics Schleswig-Holstein,
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Phagocytosis of apoptotic cells by macrophages or dendritic cells
has been shown to regulate immune responses both in vivo and in
vitro. Extracorporeal photopheresis (ECP) involves the clinical
reinfusion of peripheral blood leukocytes that are undergoing ap-
optosis following exposure ex vivo to 8-methoxypsoralen (8-MOP)
and UVA light. ECP is approved for the palliative treatment of
cutaneous T-cell lymphoma and has been reported to have utility
in immune-mediated inﬂammatory diseases, such as graft-versus-
host disease (GvHD) and solid-organ transplant rejection, and
autoimmune diseases, such as rheumatoid arthritis and Crohn’s
disease. We have evidence to suggest that ECP therapy may mod-
ulate host dendritic cell function and induce regulatory T-cell
generation. When coincubated with ECP-treated cells, activated
dendritic cells produce reduced levels of proinﬂammatory cyto-
kines, such as interleukin-12, whereas transforming growth fac-
tor- levels are modestly increased. Activation of CD4 T cells in
the presence of allogeneic dendritic cells and ECP-treated cells
promotes generation of a population of T cells that can suppress
proliferation of naive syngeneic T cells, as well as suppress inter-
feron- production. To conﬁrm these ﬁndings in vivo, we used a
murine contact hypersensitivity model. ECP-treated or control
leukocytes from mice sensitized with the hapten dinitroﬂuoroben-
zene (DNFB) were injected intravenously into naive recipients.
Compared with controls, mice that received ECP-treated cells
demonstrated signiﬁcantly less ear swelling after sensitization and
challenge with DNFB. Suppression of ear swelling was speciﬁc for
DNFB and was cell-mediated, as demonstrated by the ability to
transfer DNFB tolerance to naive mice, which could appropriately
respond to the unrelated hapten oxazalone. Transfer of this toler-
ance was abrogated by depletion of either CD4 or CD25T-cell
populations. Collectively, these results suggest that the delivery of
ECP-treated cells promotes generation of regulatory T cells that
are capable of modulating immune responses. Regulatory T cells
have been implicated in the control of GvHD, and as previously
reported, ECP has demonstrated beneﬁcial activity in GvHD. As a
result, international phase II clinical trials are currently underway
to assess the efﬁcacy of photopheresis in GvHD patients.
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PRETRANSPLANT RECIPIENT BLOOD CD14 PREDC LEVELS CORRE-
LATE WITH INCREASED ACUTE GVHD AFTER ALLOGENEIC PBSC
TRANSPLANTATION
Arpinati, M.1; Giannoullia, P.1; Chirumbolo, G.1; Bonifazi, F.1; Saun-
thararajah, Y.2; Bandini, G.1; Stanzani, M.1; Baccarani, M.1; Rondelli,
D.2 1. Research Center for Transplant Immunology, Institute of Hema-
tology, University of Bologna, Bologna, Italy; 2. Section of Hematology/
Oncology, University of Illinois at Chicago, Chicago, IL.
Host dendritic cells (DCs) present host alloantigens to donor T
lymphocytes. Human peripheral blood contains various circulating
DC precursors including CD11c myeloid preDC (mDC),
CD14 monocytic DC precursors (CD14 preDC) and plasma-
cytoid preDC (pDC). We used ﬂow cytometry to enumerate both
mDC (lin-, HLA-DR, and CD11c), mono-DC (CD14), and
pDC (lin-, HLA-DR, and CD123) numbers in the blood of
patients receiving an allogeneic HSCT. Fifty consecutive patients
undergoing HSCT from HLA-matched related (n  28) or unre-
lated (n  22) donors were enrolled in the study. The stem cell
source was bone marrow in all unrelated donors, and branulocyte
colony-stimulating factor (G-CSF) mobilized PBSC in related do-
nors. All patients received CsA and MTX as GVHD prophylaxis.
Moreover, 26 patients (52%) received ATG before transplant.
mDC and pDC PB counts were signiﬁcantly lower in patients than
in 28 age-matched healthy controls (8.8 cells/l [25th-75th per-
centile, 3.5–14.5] mDC, and 2.8 [1.3–5.5] pDC, versus 15.5 [12.1–
25.1] and 8.6 [5.6–13.1], respectively; P  .001). However the
mDC/pDC ratio was signiﬁcantly higher in the patient group (3.5
[1.6–6.2] vs 1.7 [1.3–2.6]; P  .002). CD14 preDC counts were
not signiﬁcantly different. Among the 46 patients who were evalu-
able, 12 (26%) developed acute GVHD grade II-IV. Risk factors
signiﬁcantly associated with acute GVHD were older age (P 
.01), PBSC transplantation (P  .02), and the absence of ATG in
the conditioning regimen (P  .01). Patients with acute GVHD
had signiﬁcantly higher pretransplantation mDC:pDC ratio (5.7
[3.3–16.4] vs 3.1 [1.6–5.5]; P  .03) and CD14 preDC counts
(395 [326–625] vs 284 [187–395]; P  .02). A subset analysis was
performed in PBSC patients, only 3 of whom had received ATG
before transplant. Among 26 evaluable patients, 10 (38%) devel-
oped acute GVHD grade II-IV. Besides older age (P  .02), the
only risk factors signiﬁcantly associated with acute GVHD in
PBSC patients were the pretransplantation mDC:pDC ratio (5.7
[4.1–13.1] vs 1.7 [1.2–2.9]; P  .008) and CD14 preDC counts
(395 [352–710] vs 259 [199–314]; P  .004). In multivariate anal-
ysis, only older age (P  .04) and pretransplantation circulating
CD14 preDC numbers (P  0.04) were signiﬁcantly associated
with acute GVHD in PBSC transplants. These ﬁndings demon-
strate that blood levels of DC precursors may correlate with a
higher risk of developing aGVHD. Future studies will be aimed at
depleting host preDC before allotransplant as a means of GVHD
prophylaxis.
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ACUTE AND CHRONIC GRAFT-VERSUS-HOST DISEASE (GVHD) IN PA-
TIENTS UNDERGOING ALLOGENEIC BMT FOR THALASSAEMIA MAJOR
George, B.; Mathews, V.; Viswabandhya, A.; Kavitha, N.; Srivastava,
A.; Chandy, M. Department of Haematology, Christian Medical College,
Vellore, Tamilnadu, India.
Methods: Between October 1991 and June 2004, 152 thalasse-
mic patients who underwent allogeneic BMT and survived more
than 2 weeks were evaluated for graft-versus-host disease
(GVHD). Conditioning regimens included cusulfan (Bu) 16 mg/
kg, cyclophosphamide (Cy) 200 mg/kg, and antilymphocyte glob-
ulin (ALG) 120 mg/kg (in 91 patients); Bu 600 mg/m2 and Cy 200
mg/kg (in 51 patients), Bu 14 mg/kg, Cy 10 mg/kg, and ALG 120
mg/kg (in 8 patients), and others (in 2 patients). GVHD prophy-
laxis consisted of cyclosporine (CSA) alone in 11 patients, CSA and
methotrexate (MTx) (15 mg/m2 on day 1, 10 mg/m2 on days 3, 6,
and 11) in 40 patients and CSA and MTx (10 mg/m2 on day 1, 7
mg/m2 on days 3, 6, and 11) in 99 patients. All donors were 6
antigen HLA-matched sibling (91.4%) or family (8.6%) donors.
Results: There were 103 males and 49 females, with mean age of
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6 years (range, 2–24 years). The majority were Lucarelli class III
(56%), with 38% class II and 6% class I. Median cell dose was
4.4  108 nucleated cells/kg (range, 2.1–19.7). Acute GVHD was
seen in 79 patients (51.9%) at a median time of 22.8 days (range,
7–96) after bone marrow transplantation. Grade I GVHD was seen
in 24%; grade II-IV GVHD, in 76%; grade III–IV GVHD, in
29%. Skin was involved in 69 patients (87.3%); the gastrointestinal
(GI) tract, in 38 (48%); and the liver, in 26 (32.9%). Eight patients
(10.1%) expired due to either progressive GVHD or cytomegalo-
virus infection infection, whereas the mortality rate in patients with
grade IV GVHDwas 25%. Of the evaluable 115 patients, 28 (24%)
developed chronic GVHD, which was limited in 25 (89.2%) and
extensive in 3 (10.8%). The skin was involved in 50% of the
patients, the GI tract in 64.2%, and the liver in 21%, with pulmo-
nary GVHD in 1 patient. GVHD-related mortality was seen in 2
patients (7.1%). No risk factors, including patient age, donor age,
sex mismatch, Lucarelli class, conditioning regimen, cell dose,
bacterial infections, VOD, and doses of MTx given were identiﬁed.
Reduction in the MTx dose from 15 to 10 mg/m2 did not increase
the risk of acute GVHD. In patients with acute GVHD, female to
male donor sex mismatch and cyclosporine-alone prophylaxis were
associated with an increased risk of developing grade III or IV
GVHD. The only risk factor identiﬁed for chronic GVHD was
acute GVHD. At median follow-up of 50 months (range, 3–145
months), 73.4% of patients with GVHD and 72.6% of patients
without GVHD were alive. GVHD is a major problem in patients
undergoing allogeneic BMT for thalassemia, although it is not
associated with increased mortality or secondary graft rejection.
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SEQUENTIAL BLOCKADE AND ENGAGEMENT OF COSTIMULATORY
PATHWAYS: A POTENTIAL STRATEGY FOR AMPLIFYING GRAFT-VER-
SUS-LEUKEMIA RESPONSES WITHOUT GRAFT-VERSUS-HOST DISEASE
Chakraverty, R.1; Buchli, J.1; Zhao, G.1; Hsu, R.1; Croft, M.2; Sykes,
M.1 1. Transplantation Biology Research Center, Massachusetts General
Hospital, Boston, MA; 2. La Jolla Institute for Allergy and Immunology,
San Diego, CA.
One potential approach for the effective disengagement of graft-
versus-leukemia (GVL) effects from graft-versus-host disease
(GVHD) after bone marrow transplantation (BMT) is the use of
nonmyeloablative (NM) conditioning to induce mixed chimerism
as a platform for the delayed transfer of donor T cells. In preclin-
ical models, CD8 T cells derived from donor leucocyte infusions
(DLIs) can induce powerful responses against tumors of host ori-
gin, but the effect lacks durability such that a rechallenge with
tumor inevitability leads to tumor progression and death. This
deﬁcit is associated with the failure of functional CD8 effector/
memory T cells (TE/M) to survive long-term post-DLI. We rea-
soned that strategies that augment the survival of GVH TE/M
might enhance the durability of the GVL response and, in the
absence of tissue inﬂammation induced by conditioning, might not
induce GVHD. One potential strategy is costimulation through
the tumor necrosis family receptor, OX40, which is expressed on
activated T cells, is antiapoptotic, and enhances recruitment of
TE/M to the memory pool. To test the feasibility of this approach,
we ﬁrst established mixed hematopoietic chimeras (MCs) in
B6D2F1 recipients using an NM protocol (3 Gy TBI intraperito-
neal injections of anti-CD154 and anti-CD8 monoclonal antibody
(mAb) on day 0), followed by infusion of 2  107 C57BL/6 bone
marrow cells. Ten weeks later, after the mAb had cleared from the
circulation, MC received DLI followed 2–5 days later by intraperi-
toneal injection of agonistic OX40 or control mAb. Administration
of OX40 mAb was associated with more rapid and more consistent
conversion to full donor chimerism induction as compared with
control mAb. By administering DLI that included CD8 T cells
from 2C transgenic mice that bear T-cell receptors speciﬁc for
recipient class I major histocompatibility complex Ld, we observed
that OX40 costimulation was associated with marked increases in
the numbers of 2C CD8 T cells in spleen, blood, lymph node,
and bone marrow and increased intracellular expression of inter-
feron-. By day 60 post-DLI, antihost CTL activity was clearly
detectable in anti-OX40 recipients but not in controls. Impor-
tantly, the enhancement of the magnitude and durability of the
GVH reaction could be achieved without the induction of signif-
icant clinical or histological GVHD. We conclude that OX40
costimulation after delayed DLI to established MC represents a
potential means of enhancing the magnitude and duration of a
GVH reaction, and hence GVL, without the induction of signiﬁ-
cant GVHD.
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CLONAL EXPANSION BUT IMPAIRED TRAFFICKING OF GVH-REACTIVE
T CELLS FOLLOWING DELAYED DLI TO MIXED CHIMERAS
Chakraverty, R.1; Buchli, J.1; Zao, G.1; Lin, C.; Sykes, M.1 1. Trans-
plantation Biology Research Center, Massachusetts General Hospital,
Boston, MA; 2. Wellman Center for Photomedicine, Massachusetts Gen-
eral Hospital, Boston, MA.
Donor leucocyte infusions (DLI) given to established mixed
chimeras (MCs) can eliminate normal and malignant hematopoi-
etic cells without causing graft-versus-host disease (GVHD). DLI
given immediately after lethal irradiation leads to severe GVHD.
We examined the expansion, differentiation, and in vivo trafﬁcking
of GVH-reactive T cells after delayed DLI and compared these
outcomes when identical DLI was administered early after lethal
irradiation (TBI). C57BL/6 (B6) CD45.2  BALB/c 3 BALB/c
MC were prepared by TBI of BALB/c recipients and reconstitu-
tion with T-cell depleted bone marrow (TCD BM) derived from
donor and recipient strains. Ten weeks later, 107 CD45.1 B6 and
5 106 2C transgenic splenocytes were transferred. CD8 T cells
from 2C transgenic mice bear TCR speciﬁc for recipient class I
MHC Ld and can be detected using a clonotypic marker. For
comparison, identical DLI together with TCD BM was adminis-
tered to freshly irradiated BALB/c or B6 CD45.2 syngeneic recip-
ients. After delayed DLI, expansion of donor CD4 cells (on peak
day 10) preceded expansion of CD8 cells (on peak day 13) in the
spleen, with less accumulation in the lymph nodes, BM, liver and
lung, and no accumulation in the gut. In contrast, the kinetics of
donor T-cell expansion were more rapid in freshly irradiated re-
cipients with T cell responses peaking on day 4–7. Major trafﬁck-
ing of donor T cells to the gut was observed. After delayed DLI,
the kinetics of 2C CD8 T cell expansion were similar to those of
the polyclonal CD8 T-cell population. 2C CD8 T cells ac-
quired a memory/activation phenotype (CD44hi, CD45RBlo,
CD62Llo, CD49d, CD27, 47high) to a similar extent as
those in TBI mice developing GVHD. In additional experiments,
we transferred 4  106 B6 GFP T cells to freshly irradiated B6
xDBA/2 (B6D2F1) or B63B6D2F1 established MC and imaged
trafﬁcking to skin in real time by 2-photon imaging of postcapillary
venules of recipient ear pinnae. By day 5, we observed marked
rolling, tethering/adhesion, and extravasation of GFP T-cells in
freshly irradiated recipients. In contrast, GFP T cells failed to
trafﬁc to the skin on day 5 or 12 after transfer to established MC
despite their presence within the peripheral blood. Thus, in con-
trast to the response in freshly irradiated mice that develop
GVHD, GVH reactions induced by delayed DLI are characterized
by similar clonal expansion but failure of GVH-reactive T cells to
trafﬁc to the skin or the gut.
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RITUXAN FOR STEROID-REFRACTORY CHRONIC GVHD
Cutler, C.1; Miklos, D.2; Lee, S.J.1; Woo, S.-B.1; Treister, N.1; Bien-
fang, D.1; Klickstein, L.1; Levin, J.1; Windawi, S.1; Pasek, M.1; Ho,
V.1; Ritz, J.1; Antin, J.1; Soiffer, R.1; Alyea, E.1 1. Dana Farber Cancer
Institute and Brigham and Women’s Hospital, Harvard Medical School,
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Donor-derived T cells are thought to be the primary effectors of
chronic graft-versus-host disease (cGVHD); however, additional
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